Abstracts - faqs.org

Abstracts

Business, general

Search abstracts:
Abstracts » Business, general

Merck reports positive test results for new type of antidepressant drug

Article Abstract:

Merck and Company Inc has announced preliminary findings that its experimental antidepressant MK-869 relieves depression as well as Paxil but with fewer side effects. Paxil produced sexual side effects in 26% of the 210 patients, while MK-869 caused sexual side effects in only 3% of patients. Unlike the currently popular selective serotonin reuptake inhibitors, MK-869 fights depression by blocking a brain chemical called substance P. Pfizer Inc, Eli Lilly and Co, and Novartis are also testing or planning to test substance P blockers.

Comment:

Reports early findings that MK-869 relieves depression as well as Paxil, with fewer side effects

Author: Langreth, Robert
Publisher: Dow Jones & Company, Inc.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
Science & research, Company Planning/Goals, Antidepressant Preparations, Antidepressants, Merck & Company Inc., Article

User Contributions:

1
Julie
Report this comment as inappropriate
Nov 5, 2009 @ 10:10 am
Interesting... if this was published in 1998, then it was three years before the patent on Paxil was officially up -- so perhaps what Merck was attempting to do was to was to prove PAXIL to be ineffective in comparision with their new drug, thus by the time the patent was up, no one would WANT to try and make generic PAXIL -- thus grabbing the stranglehold on the market. Brilliant! If only it had worked. Other sources indicate that research on this drug was aborted months later... get some better research and developers, Merck!

Comment about this article or add new information about this topic:

CAPTCHA

Hoechst to intensify marketing battle with Immunex Corp. on arthritis drug

Article Abstract:

Hoechst AG hopes it has the edge in promoting its Arava, the updated drug treatment for rheumatoid arthritis which afflicts about 2.5 million Americans. One study showed that Arava slowed bone erosion by more than 75% over placebos. Side-effects may be more serious, though, than side-effects from taking the new drug, Enbrel, Arava's main competitor. Cost difference, however, is in Arava's favor. Arava can cost a patient about $3,000 a year compared with Enbrel's $10,000 per year.

Author: Langreth, Robert
Publisher: Dow Jones & Company, Inc.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
Marketing procedures, New Products/Services, Pharmaceutical preparations, Demographics, Antiinflammatory Drugs, Drugs, Pharmaceutical industry, Marketing, Abstract, Arthritis, Anti-inflammatory agents, Hoechst AG

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States
Similar abstracts:
  • Abstracts: America Online kicks off latest drive for members with new wave of disks. For those who scoff at Internet commerce, here's a hot market; raking in millions, sex sites use old-fashioned porn and cutting-edge tech; lessons for the mainstream
  • Abstracts: Murdoch reported to have bid $950 million for Britain's richest soccer club. BMW to get Rolls-Royce after all by acquiring the name
  • Abstracts: Some SUVs flip on side in crash test. Flights on nearly 75% of major routes take longer than those of decade ago
  • Abstracts: Looming over Northwest talks: other unions. UAL's search for next chief comes down to two. AirTran flight attendants prepare for possible strike
  • Abstracts: I.B.M. earnings beat analysts' estimates; revenues from mainframes declined but software was up 9%
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.